Announcement details OTHERS MTOUCHE TECHNOLOGY BERHAD ("MTOUCHE" OR "THE COMPANY") - MEDICAL DEVICE AUTHORITY ("MDA"), MALAYSIA QUERY AND CLARIFICATION. For consistency purposes, the abbreviations and definitions used throughout this announcement shall have the same meanings as those previously defined in the Company’s announcements dated 14 April 2020 and 13 November 2020. Further to the Company’s announcements made on 14 April 2020 and 13 November 2020 pertaining to the Novel Coronovirus (SAR-Cov-2) RT-PCR Detection and Diagnostic Kit (COVID-19 Test Kits) have received the MDA’s “Recommended for Use”, with recent query and clarification received from the MDA on 23 November 2020, the Board of the Directors of the Company wishes to clarify and correct the following misstatement. Under the MDA’s Special Access, no promotional and advertising activities is allowed without prior approval from the MDA. Chapter 9.12(1) of the ACE Market Listing Requirements (“ACE LR”) provides that a listed corporation must refrain from promotional disclosure activity in any form whatsoever or howsoever which may mislead investors or cause unwarranted price movement and activity in a listed corporation’s securities.
The Company wishes to clarify and confirm that the announcement made by the Company on 13 November 2020 is a continuing disclosure pursuant to Chapter 9.02(2)(a) of the ACE LR and the Company does not have any intention or motivation on any promotional related activities.
Besides, please be informed that the Company does not possess the MDA’s Establishment License and Good Distribution Practice for Medical Devices (GDPMD) currently. The Company is collaborating with Premier Diagnostics Sdn. Bhd. who holds the MDA’s Establishment License to apply for the Special Access from the MDA.
With further clarification received from the MDA, the Company is not allowed to “promote, market, distribute” as well as import any of the “Recommended for Use” COVID-19 Test Kits as the Company is not the registered holder for MDA’s Establishment License. Hence, the Company will continue to collaborate with its partner, Premier Diagnostics Sdn. Bhd. for the importation, warehousing and logistic support and the Company may collaborate with other MDA’s Establishment License Distributors for the distribution of the COVID-19 Test Kits.
TEST KITS: NEXGRAM' CASE - THE APPROVAL HAS BEEN GRANTED BY THE AUTHORITIES
1. The product was submitted to Indonesia authority under pandemic emergency use and import approval was obtained within 14 days.
2. TRI-G is a licensed medical device distributor and had obtained Malaysia master authorisation to distribute Novel Coronavirus (2019-nCoV) IgM/IgG Rapid Test Kit, and Novel Coronavirus (2019-nCoV) RT-qPCR Detection and Diagnostic Kit. TRI-G is currently already distributing Malaysia Medical Device Authority (MDA) special access approved Novel Coronavirus (2019-nCoV) IgM/IgG Rapid Test Kit to medical centres right after 18 March 2020 the start of movement control order (MCO).
3. TRI-G is a company registered with the Medical Device Authority (MDA), supplying medical equipment to government and private hospitals, as well as authorized distributor for Covid-19 PCR test and RTK antibody test kits approved by Ministry of Health (MOH), including International brands such as Healgen and Liangrun.
Yesss. Nexgram.... semua ada... NexgramBottleVaccine (via subsidiary operation) Tracvirus with tracking vaccination is ready (contract with MOH) Covid-19 VACCINE sale & distributorships........... (high possibility)
and, Covid-19 Test Kits (agreement with MKN/MOH and MTC) Covid-19 Test (via subsidiary in Indonesia) Tracvirus SafeTravelPass (contract with MOH) Medical gloves and PPE (gown) (contract with MAPU in Indonesia)
Kuala Lumpur, 28 October 2020 : Nexgram Biomedic unit Medical Brands Inc (MBI) inked Strategic Cooperation Head of Agreement (SCHOA) with Mcio BioMed Ltd (Mico BioMed) on 12 October, 2020, in mutual interest in an exclusive licensing agreement and/or forming a joint venture to (a) prepare On-Site solution for Covid-19 PCR test for MBI Contract Award using TRACVIRUS E-Cert platform (“CONTRACT-AWARD”), and (b) develop and operate retail medical devices distribution under the Mico BioMed name dedicated to selling Mico BioMed Veri-Q Prep & PCR machines, extraction, kits, PCR reagents, and compatible products especially for Covid-19 testing (collectively “Covid-19 Test Solutions” or “SOLUTION”) to consumers over the MBI Indonesia business unit.
EXTREMELY STRONG SUPPORT MOM NEXGRAM @ 5 SEN while EXPLOSIVE WARRANT. WC @3 SEN.... RUMOURS OF SOLID POSITIVE QUARTER RESULT END DECEMBER MAKING MANY COLLECTING FOR POTENTIAL HIGH % YEAR END / CNY - CHINESE NEW YEAR ANGPOWS
actually ozura is nothing...but sideliners need some prove that their projects really productive...that's all....when vol. come...ozura just like ikan bilis only.....kikikikikih
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
DRwarrant
8,354 posts
Posted by DRwarrant > 2020-12-01 15:04 | Report Abuse
Just to frightened weak holders/pondan such as 8dragon / OKU_2020...